Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis

Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …

Find out details on these three critical Nvidia partners immediately.

George Lloyd Biography and Net Worth

EVP of Royalty Pharma

Mr. Lloyd focuses on transaction structuring and execution and also leads the legal and compliance function at Royalty Pharma. Mr. Lloyd joined Royalty Pharma in 2011 after representing Royalty Pharma on all transactional work since 2006. Mr. Lloyd was previously a partner in Goodwin Procter’s Private Equity Group and an associate in Davis, Polk & Wardwell’s New York and Paris offices. Mr. Lloyd has an AB from Princeton University and a JD from New York University Law School.

What is George W. Lloyd's net worth?: The estimated net worth of George W. Lloyd is at least $2.72 million as of June 5th, 2023. Mr. Lloyd owns 109,099 shares of Royalty Pharma stock worth more than $2,718,747 as of December 21st. This net worth estimate does not reflect any other investments that Mr. Lloyd may own. Additionally, Mr. Lloyd receives an annual salary of $4,560,000.00 as EVP at Royalty Pharma. Learn More about George W. Lloyd's net worth.
How old is George W. Lloyd?: Mr. Lloyd is currently 64 years old. There are 5 older executives and no younger executives at Royalty Pharma. Learn More on George W. Lloyd's age.
What is George W. Lloyd's salary?: As the EVP of Royalty Pharma plc, Mr. Lloyd earns $4,560,000.00 per year. Learn More on George W. Lloyd's salary.
How do I contact George W. Lloyd?: The corporate mailing address for Mr. Lloyd and other Royalty Pharma executives is 110 E 59th Street, New York NY, 10022. Royalty Pharma can also be reached via phone at 212-883-0200 and via email at [email protected]. Learn More on George W. Lloyd's contact information.
Has George W. Lloyd been buying or selling shares of Royalty Pharma?: George W. Lloyd has not been actively trading shares of Royalty Pharma during the last quarter. Most recently, George W. Lloyd sold 19,215 shares of the business's stock in a transaction on Monday, June 5th. The shares were sold at an average price of $33.54, for a transaction totalling $644,471.10. Following the completion of the sale, the executive vice president now directly owns 109,099 shares of the company's stock, valued at $3,659,180.46. Learn More on George W. Lloyd's trading history.
Who are Royalty Pharma's active insiders?: Royalty Pharma's insider roster includes Terrance Coyne (CFO), Henry Fernandez (Director), William Ford (Director), Mario Giuliani (Director), Pablo Legorreta (Founder & Chief Executive Officer and Chairman), George Lloyd (EVP), James Reddoch (EVP), Rory Riggs (Director), Sanjay Singh (CRO), and Marshall Urist (EVP). Learn More on Royalty Pharma's active insiders.
Are insiders buying or selling shares of Royalty Pharma?: In the last twelve months, insiders at the biopharmaceutical company sold shares 3 times. They sold a total of 312,631 shares worth more than $8,860,323.39. The most recent insider tranaction occured on January, 4th when Director Rory B Riggs sold 35,702 shares worth more than $983,590.10. Insiders at Royalty Pharma own 18.9% of the company. Learn More about insider trades at Royalty Pharma.
Information on this page was last updated on 1/4/2024.

George W. Lloyd Insider Trading History at Royalty Pharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/5/2023	Sell	19,215	$33.54	$644,471.10	109,099
6/2/2023	Sell	93,907	$33.64	$3,159,031.48	120,000
3/28/2023	Sell	100,000	$37.06	$3,706,000.00	225,000
11/21/2022	Sell	23,631	$43.11	$1,018,732.41	144,469
11/10/2022	Sell	50,000	$43.85	$2,192,500.00	165,000
8/9/2022	Sell	11,859	$43.92	$520,847.28	210,109
7/27/2022	Sell	25,100	$43.76	$1,098,376.00	226,014
7/25/2022	Sell	30,671	$42.93	$1,316,706.03	228,886
5/23/2022	Sell	100,000	$40.27	$4,027,000.00	530,000
11/16/2021	Sell	165,852	$42.39	$7,030,466.28
7/26/2021	Sell	13,362	$39.78	$531,540.36
7/12/2021	Sell	100	$42.04	$4,204.00	3,000
6/10/2021	Sell	70,000	$46.49	$3,254,300.00	3,000
4/14/2021	Sell	69,822	$42.13	$2,941,600.86	3,000
4/12/2021	Sell	449	$42.32	$19,001.68	3,000
3/2/2021	Sell	125,000	$46.94	$5,867,500.00	3,000
6/18/2020	Buy	3,000	$28.00	$84,000.00	3,000

George W. Lloyd Buying and Selling Activity at Royalty Pharma

Royalty Pharma Company Overview

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Today's Range

Now: $24.92

$24.32

$25.00

50 Day Range

MA: $26.43

$24.28

$28.22

2 Week Range

Now: $24.92

$24.05

$31.66

Volume

7,574,639 shs

Average Volume

2,691,117 shs

Market Capitalization

$14.68 billion

P/E Ratio

12.91

Dividend Yield

3.43%

Beta

0.46

Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis

From Weiss Ratings | Ad

Find out details on these three critical Nvidia partners immediately.

George Lloyd Biography and Net Worth

What is George W. Lloyd's net worth?

How old is George W. Lloyd?

What is George W. Lloyd's salary?

How do I contact George W. Lloyd?

Has George W. Lloyd been buying or selling shares of Royalty Pharma?

Who are Royalty Pharma's active insiders?

Are insiders buying or selling shares of Royalty Pharma?